Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2023-09-21 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于公司控股股东、实际控制人自愿承诺不减持公司股份的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from the company Meikang Biotechnology Co., Ltd. regarding a voluntary commitment by the controlling shareholder and actual controller, Mr. Zou Bingde, not to reduce his shareholding in the company for the next 6 months. It includes details about the shareholder's holdings, the commitment period, and legal responsibilities. The document is short (1047 characters) and is an announcement about shareholding behavior rather than a financial report or detailed regulatory filing. It does not contain financial statements, audit information, or management discussion. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best with the category of Major Shareholding Notification (MRQ), which covers notifications of changes or commitments regarding significant share ownership levels.
2023-09-21 Chinese
关于向全资子公司划转相关资产暨增资的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Meikang Biotechnology Co., Ltd. regarding the progress of asset transfer and capital increase to its wholly-owned subsidiary. It details the board meeting resolution, asset valuation, registration capital changes, and approvals obtained. The document does not contain financial statements or detailed financial performance data but rather informs about corporate actions related to asset transfer and capital increase. The length is short (1854 characters) and it is an announcement of progress rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2023-09-08 Chinese
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a medical device registration certificate issued by a regulatory authority (Zhejiang Provincial Drug Administration). It includes details about the certificate, product, and its potential impact on the company's business. The document is short (848 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an official announcement about a regulatory approval rather than a financial report or management update. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-09-01 Chinese
关于变更保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the company's sponsor representatives for a specific stock issuance project. It includes details about the replacement of a sponsor representative and provides a brief resume of the new representative. There are no financial statements, earnings data, or detailed report content. The document is short (1117 characters) and serves as a formal notification of a management-related change concerning sponsor representatives. This fits best under Board/Management Information (MANG), as it relates to changes in key company representatives involved in regulatory sponsorship and oversight roles.
2023-09-01 Chinese
关于为全资孙公司提供担保的补充公告
Regulatory Filings Classification · 95% confidence The document is a supplementary announcement regarding a previous guarantee announcement for a wholly-owned subsidiary. It provides additional details about the subsidiary's basic information and unaudited financial indicators. The document references a prior announcement (2023-056) and states that the full updated announcement is available on the regulatory disclosure website. The document length is short (1483 characters) and it serves to supplement and clarify a prior announcement rather than presenting a full financial report or detailed financial statements. It is not an annual report, interim report, or earnings release. It is also not a certification or officer attestation. The document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement supplementing a prior disclosure and does not constitute a full report or financial statement itself.
2023-08-24 Chinese
关于向全资子公司划转相关资产暨增资的公告（补充后）
Capital/Financing Update Classification · 95% confidence The document is an announcement by 美康生物科技股份有限公司 regarding the transfer of assets and capital increase to its wholly-owned subsidiary 宁波瑞合院生物科技有限公司. It details the asset transfer, valuation, board approval, and the impact on the company. The document is structured as a formal announcement with no financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is not a call transcript or a legal proceeding report. The content focuses on a capital/financing update related to internal asset transfer and capital increase within the corporate group. The document length is about 4893 characters, which is sufficient for a full announcement but not a full financial report. Therefore, the best fitting category is Capital/Financing Update (CAP).
2023-08-24 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.